Pharmaceutical Industry Report - Clinical Report, Drug R&D Report, Pharmaceutical Information

Global Drug R&D Express (Nov 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of November totaling 132 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (October 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of October totaling 132 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (September 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of August totaling 119 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Aug 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of August totaling 124 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (July 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of July totaling 110 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (May 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of May totaling 95 drugs. Among them, 1 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (June 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of June totaling 89 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Apr 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of April totaling 90 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Mar 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 93 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →